3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 2/3
1
Status
Completed
19
Recruiting
3
Withdrawn
2
Unknown
1
Terminated
1
Active not recruiting
1
Sponsor Class
OTHER
3
Study Type
Interventional
3
Sponsor
Cancer Type
Lymphoid
3
Conditions
Multiple Myeloma
87
Precursor Cell Lymphoblastic Leukemia-Lymphoma
21
Recurrence
16
Burkitt Lymphoma
13
Neoplasms
10
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
8
Leukemia, Biphenotypic, Acute
7
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
6
Lung Neoplasms
6
Immunoglobulin Light-chain Amyloidosis
6
Neoplasms, Plasma Cell
5
Hodgkin Disease
5
Smoldering Multiple Myeloma
4
Leukemia
4
Carcinoma, Non-Small-Cell Lung
4
Waldenstrom Macroglobulinemia
3
Triple Negative Breast Neoplasms
3
Prostatic Neoplasms
3
Neoplasm Metastasis
3
Nausea
3
Lymphoma, Large B-Cell, Diffuse
3
Lymphoma
3
Brain Neoplasms
3
Renal Insufficiency
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Ovarian Neoplasms
2
Lymphoma, T-Cell, Peripheral
2
Lymphoma, T-Cell
2
Lymphoma, B-Cell
2
Leukemia, Plasma Cell
2
Interventions
Rituximab
7
zanubrutinib
6
venetoclax
5
ibrutinib
3
Dexamethasone
3
pirtobrutinib
2
Specimen Handling
2
Magnetic Resonance Spectroscopy
2
Cyclophosphamide
2
Blood Specimen Collection
2
Biopsy
2
Bendamustine Hydrochloride
2
obinutuzumab
1
Positron-Emission Tomography
1
Lenalidomide
1
Exercise
1
Diet
1
CT-P10
1
Bortezomib
1
ARQ531
1
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Recruiting
×
Waldenstrom Macroglobulinemia
×
Dexamethasone
×
Clear all
NCT05099471
2026-05-05
VIWA-1
University of Ulm
Phase 2
Recruiting
80 enrolled
NCT04061512
2024-05-10
RAINBOW
University College, London
Phase 2/3
Recruiting
148 enrolled
NCT03697356
2023-10-06
Ballondor
Kosin University Gospel Hospital
Phase 2
Recruiting
54 enrolled